便秘型肠易激综合征(irritable bowel syndrome with constipation,IBS-C)主要表现为腹痛、排便不畅或大便次数减少,西药主要以解痉药、氯离子通道激活剂、鸟苷酸环化酶激活剂等药物为主,但症状易反复,中医治疗逐渐成为IBS-C的潜在疗法...便秘型肠易激综合征(irritable bowel syndrome with constipation,IBS-C)主要表现为腹痛、排便不畅或大便次数减少,西药主要以解痉药、氯离子通道激活剂、鸟苷酸环化酶激活剂等药物为主,但症状易反复,中医治疗逐渐成为IBS-C的潜在疗法。基于肝脾同调治法,从理法方药结合现代实验数据研究的角度,认为“白术-白芍”药对在IBS-C的治疗中应用值得推广,以期为IBS-C的治疗提供标本兼治、简便有效的中医思路。展开更多
Atractylodes macrocephala Koidz.(A.macrocephala)is a medicinal and edible plant species belonging to the Compositae family.Its rhizome serves both therapeutic and nutritional purposes in China.This investigation led t...Atractylodes macrocephala Koidz.(A.macrocephala)is a medicinal and edible plant species belonging to the Compositae family.Its rhizome serves both therapeutic and nutritional purposes in China.This investigation led to the isolation of thirteen novel rearranged 9(8→7)-abeo-eudesmane-type sesquiterpenoid dimers(SDs),atramacronins A-M(1-13),three eudesmane-type SDs,atramacronins N-P(14-16),and two previously identified meroterpenoids,atrachinenin G(17)and atrachineninΙ(18),from Atractylodes macrocephala.Structure elucidation was accomplished through comprehensive spectroscopic analysis and single-crystal X-ray diffraction.Compounds 1,4-7,9,and 10 exhibited notable cytotoxicity against Hep3B,HepG2,and Huh7 cell lines,with half maximal inhibitory concentration(IC_(50))values ranging from 3.71 to 13.99μmol·L^(-1).展开更多
Ulcerative colitis (UC) is a persistent,diffuse intestinal inflammation and ranks among the most challenging chronic diseases worldwide.Atractylodes lancea (Thunb.) DC.and Atractylodis macrocephala Koidz.are tradition...Ulcerative colitis (UC) is a persistent,diffuse intestinal inflammation and ranks among the most challenging chronic diseases worldwide.Atractylodes lancea (Thunb.) DC.and Atractylodis macrocephala Koidz.are traditional Chinese medicines (TCMs) with a long history of clinical application,particularly for gastrointestinal disorders.Both Atractylodis Rhizoma (AR)and Atractylodis Macrocephala Rhizoma (AM) have shown significant efficacy in managing UC;however,the underlying mechanism by which the AR-AM herbal pair promotes intestinal mucosal healing remains poorly understood.The therapeutic effects of the ethanolic extract of AR-AM (EEAR-AM) were evaluated in a murine UC model induced by dextran sodium sulfate(DSS).A network pharmacology approach was employed to explore the anti-UC properties of EEAR-AM,including identification of active compounds,prediction of potential targets,and construction of a protein-protein interaction (PPI) network.Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were subsequently performed to preliminarily elucidate the mechanisms of EEAR-AM in UC treatment.Finally,the proposed molecular mechanisms were validated in both DSS-induced UC mice and Caco-2 cells.In vivo results demonstrated that EEAR-AM significantly attenuated DSS-induced weight loss,reduced colon shortening,lowered the disease activity index (DAI) score,and modulated the spleen coefficient.Moreover,EEAR-AM improved colonic tissue architecture,reduced inflammatory infiltration,restored goblet cell density,enhanced mucin MUC2 expression,and elevated levels of tight junction (TJ) proteins.Additionally,EEAR-AM suppressed the expression of matrix metalloproteinase 2 (MMP-2) and MMP-9.Network pharmacology analyses indicated that EEAR-AM may ameliorate intestinal mucosal dysfunction through modulation of the exchange protein directly activated by cAMP 1 (Epac1)/Ras-associated protein 1 (Rap1) pathway and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathways.These actions potentially enhance cellular barrier integrity and reduce the release of inflammatory mediators.Western blotting results confirmed that EEAR-AM activated the Epac1/Rap1 pathway while downregulating the PI3K/AKT pathway in both DSS-induced UC mice and Caco-2cells,consistent with predictions from network pharmacology.This study represents the first evidence that the EEAR-AM herbal pair improves intestinal mucosal barrier function in UC,with therapeutic effects likely mediated by activation of the Epac1/Rap1 pathway and inhibition of the PI3K/AKT pathway.展开更多
文摘便秘型肠易激综合征(irritable bowel syndrome with constipation,IBS-C)主要表现为腹痛、排便不畅或大便次数减少,西药主要以解痉药、氯离子通道激活剂、鸟苷酸环化酶激活剂等药物为主,但症状易反复,中医治疗逐渐成为IBS-C的潜在疗法。基于肝脾同调治法,从理法方药结合现代实验数据研究的角度,认为“白术-白芍”药对在IBS-C的治疗中应用值得推广,以期为IBS-C的治疗提供标本兼治、简便有效的中医思路。
基金supported by the National Natural Science Foundation of China(Nos.32470414,32100319,and 82104377)the Fundamental Research Funds for the Central Universities,SWU(No.SWU-KR22052)+1 种基金the Natural Science Foundation of Chongqing,China(No.CSTB2022NSCQMSX0878)Chongqing Municipal Training Program of Innovation and Entrepreneurship for Undergraduates(No.S20241063290).
文摘Atractylodes macrocephala Koidz.(A.macrocephala)is a medicinal and edible plant species belonging to the Compositae family.Its rhizome serves both therapeutic and nutritional purposes in China.This investigation led to the isolation of thirteen novel rearranged 9(8→7)-abeo-eudesmane-type sesquiterpenoid dimers(SDs),atramacronins A-M(1-13),three eudesmane-type SDs,atramacronins N-P(14-16),and two previously identified meroterpenoids,atrachinenin G(17)and atrachineninΙ(18),from Atractylodes macrocephala.Structure elucidation was accomplished through comprehensive spectroscopic analysis and single-crystal X-ray diffraction.Compounds 1,4-7,9,and 10 exhibited notable cytotoxicity against Hep3B,HepG2,and Huh7 cell lines,with half maximal inhibitory concentration(IC_(50))values ranging from 3.71 to 13.99μmol·L^(-1).
基金supported by the Key Scientific Research Project of Hubei Provincial Department of Education (No.D20232001)。
文摘Ulcerative colitis (UC) is a persistent,diffuse intestinal inflammation and ranks among the most challenging chronic diseases worldwide.Atractylodes lancea (Thunb.) DC.and Atractylodis macrocephala Koidz.are traditional Chinese medicines (TCMs) with a long history of clinical application,particularly for gastrointestinal disorders.Both Atractylodis Rhizoma (AR)and Atractylodis Macrocephala Rhizoma (AM) have shown significant efficacy in managing UC;however,the underlying mechanism by which the AR-AM herbal pair promotes intestinal mucosal healing remains poorly understood.The therapeutic effects of the ethanolic extract of AR-AM (EEAR-AM) were evaluated in a murine UC model induced by dextran sodium sulfate(DSS).A network pharmacology approach was employed to explore the anti-UC properties of EEAR-AM,including identification of active compounds,prediction of potential targets,and construction of a protein-protein interaction (PPI) network.Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were subsequently performed to preliminarily elucidate the mechanisms of EEAR-AM in UC treatment.Finally,the proposed molecular mechanisms were validated in both DSS-induced UC mice and Caco-2 cells.In vivo results demonstrated that EEAR-AM significantly attenuated DSS-induced weight loss,reduced colon shortening,lowered the disease activity index (DAI) score,and modulated the spleen coefficient.Moreover,EEAR-AM improved colonic tissue architecture,reduced inflammatory infiltration,restored goblet cell density,enhanced mucin MUC2 expression,and elevated levels of tight junction (TJ) proteins.Additionally,EEAR-AM suppressed the expression of matrix metalloproteinase 2 (MMP-2) and MMP-9.Network pharmacology analyses indicated that EEAR-AM may ameliorate intestinal mucosal dysfunction through modulation of the exchange protein directly activated by cAMP 1 (Epac1)/Ras-associated protein 1 (Rap1) pathway and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathways.These actions potentially enhance cellular barrier integrity and reduce the release of inflammatory mediators.Western blotting results confirmed that EEAR-AM activated the Epac1/Rap1 pathway while downregulating the PI3K/AKT pathway in both DSS-induced UC mice and Caco-2cells,consistent with predictions from network pharmacology.This study represents the first evidence that the EEAR-AM herbal pair improves intestinal mucosal barrier function in UC,with therapeutic effects likely mediated by activation of the Epac1/Rap1 pathway and inhibition of the PI3K/AKT pathway.
